cancer cells outcompete macrophages for microenvironmental zinc to drive immunotherapy resistance.

Approximately 50% of cancers exhibit decreased expression ( ), which is linked to immune checkpoint blockade (ICB) resistance. While is traditionally recognized as a tumor suppressor and cell cycle regulator, we have previously put forth a new paradigm demonstrating its role in intracellular metabolic reprogramming. Whether the metabolic derangement due to loss alters metabolites within the tumor microenvironment (TME) and how that affects the immune compartment and ICB response has never been investigated.